Pharmaceutical Working Group Working Group on Pharmaceuticals Key Points for Advocacy and Action

Process 1. Identification of issues 2. Country experiences and situation sharing 3. Identification of Key Actions 4. Moving Forward

Key Issues 1. Artemisinin monotherapy 2. Cross border issues on trade 3. Supply systems: implications beyond stock outs 4. Funding Commitments

Key Actions 1. Artemisinin monotherapy High level action/s: a) Withdrawal of monotherapies including action for trade Country level actions a) Transition mechanisms from monotherapy to combined formulations b) Ensuring access and availability of AT

Key Actions 2. Cross –border issues on trade, counterfeits and Substandard medicines High Level Action a) Common regulatory framework Country level actions a) Capacity strengthening for regulatory authorities: minimum level of standards b) Post-marketing surveillance and pharmacovigilance systems

Key Actions 3. Supply systems: implications beyond stock outs High Level Action a) Regional Drug Facility: standard formulations, prices (?) Country level actions a) Securing the public sector supply b) Capacity building

Key Actions 3. Funding Commitments a) Government and donor commitments

Ways Forward 1. Policy Briefs and Call for Action 2. Guideline for actions at country level 3. Streamlining capacity building in ongoing programs 4. Measuring action ( indicators)

Thank You